Sleep apnea device for home-based diagnostics returns to MEDICA -- MEDICA Trade Fair


BresoTec Inc.

Sleep apnea device for home-based diagnostics returns to MEDICA

BresoTec Inc. offers a reliable, comfortable and affordable solution to proper sleep diagnosis

TORONTO, September 16, 2015 – BresoTec Inc. (formerly iDAPT Somno Inc.) will feature its affordable wear-at-home BresoDx (TM) (formerly ApneaDx) sleep apnea diagnostic device at MEDICA 2015, the world’s largest annual medical trade fair, November 16-19 in Düsseldorf, Germany.

First introduced at last year’s MEDICA, BresoDx is lightweight, cordless, and worn comfortably on the face while sleeping unattended at home. It captures multiple streams of a person’s sleep patterns on a chip. In turn, the company’s patented SoundTrac(TM) technology analyzes the captured data and provides diagnostic results for sleep apnea that inform better treatment and comparable to any sleep laboratory.

“We’ve renamed our device and indeed changed our company’s name to better reflect what we produce and do with all that a patient’s monitored breathing can tell you,” says Dr. Geoff Fernie, now CEO of BresoTec. Dr. Fernie is also the Institute Director of the renowned Toronto Rehabilitation Institute, Research, where its iDAPT research team spun off the sleep apnea device now known as BresoDx.

About Sleep Apnea:

Characterized by recurrent partial or complete pauses in breathing during sleep, sleep apnea is one of today’s biggest health concerns. Several studies around the world have shown that approximately 8% of the adult population has sleep apnea. If left untreated, sleep apnea could lead to a 3 to 4-fold increase in the risk of hypertension, stroke or heart failure, and up to a 4-fold increased risk of motor vehicle accidents. Furthermore, emerging evidence shows an association between sleep apnea and cancer mortality.

Currently, the gold-standard for diagnosing sleep apnea is polysomnography (PSG), a test performed in a sleep laboratory that measures the frequency of apneas and hypopneas per hour of sleep or apnea-hypopnea index (AHI). However, because PSG is expensive, inconvenient, time-consuming (6-8 hours in a sleep laboratory), uncomfortable (numerous electrodes and wiring are required), and has limited availability, the rate of sleep apnea diagnosis is very low. For example, in developed countries, less than 10% of these who have sleep apnea are diagnosed. The company believes that BresoDx provides a solution to this problem of under-diagnosis.

About BresoTec Inc:

Our innovations are driven by a world-class team of scientists and engineers led by Drs. Geoff Fernie, Douglas Bradley, and Hisham Alshaer. Dr. Fernie is a well-known inventor in the field of rehabilitation science. He is a biomedical and mechanical engineer, a professor in the Department of Surgery and the Institute of Biomaterials and Biomedical Engineering at the University of Toronto (U of T) and the Institute Director at the Toronto Rehabilitation Institute (TRI). Dr. Bradley is one of the world’s leading scientists in sleep medicine. He is the Clifford Nordal Chair in Sleep Apnea and Rehabilitation Research, a senior scientist at TRI and Toronto General Hospital, and a professor of Medicine and Director of the Division of Respirology at the U of T. Dr. Alshaer is a medical doctor and a PhD in biomedical engineering with expertise in sleep research. He is the primary inventor of BresoDx, and has been awarded numerous academic and entrepreneurial awards such as the Paul B. Madsen Award by the Institute of Biomaterials and Biomedical Engineering at the University of Toronto.

Founded by the University Health Network (UHN) and MaRS Innovation (MI), BresoTec is a Canadian start-up featuring technology developed by iDAPT Research of TRI, a member of UHN. iDAPT Research is the world’s largest research organization in rehabilitation research.

To learn more about BresoDx, please visit us during MEDICA 2015 at the Ontario/Canada Pavilion, Hall 16, Booth G50.

You can also locate us in “Companies & Products" on the portal.

Note: BresoDx has received Health Canada approval and is expected to have FDA and CE Mark by the end of 2015.

For further information, please contact:

Caren Cao
International Business Development Liaison
BresoTec Inc.
Room 12-145, 550 University Avenue
Toronto, Ontario, M5G 2A2
T: 416-597-3422 ext. 7834